ArticleJournal of virology2000
Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transduction of Epstein-Barr virus-transformed B cells.
Article in Journal of virology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 116 citations in OpenAlex.
- Insights into the structure and initial host attachment of the flagellotropic bacteriophage 7-7-1.Communications biology · 2025Article
- Preclinical evaluation of the gorilla-derived HAdV-B AdV-lumc007 oncolytic adenovirus 'GoraVir' for the treatment of pancreatic ductal adenocarcinoma.Molecular oncology · 2024Article
- Transient Chimeric Ad5/37 Fiber Enhances NK-92 Carrier Cell-Mediated Delivery of Oncolytic Adenovirus Type 5 to Tumor Cells.Molecular therapy. Methods & clinical development · 2020Article
- Article
- Article
- The effect of fiber truncations on the stability of adenovirus type 5.Molecular biotechnology · 2014Article
- Development of a novel efficient method to construct an adenovirus library displaying random peptides on the fiber knob.Molecular pharmaceutics · 2014Article
- Article
- Infectivity-selective oncolytic adenovirus developed by high-throughput screening of adenovirus-formatted library.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- ENU-induced phenovariance in mice: inferences from 587 mutations.BMC research notes · 2012Article
- Peptide targeting of adenoviral vectors to augment tumor gene transfer.Cancer gene therapy · 2012Article
- T-cell-biased immune responses generated by a mucosally targeted adenovirus-σ1 vaccine.Mucosal immunology · 2012Article
- Structure of human adenovirus.Current opinion in virology · 2012Review
- Increased susceptibility to DNA virus infection in mice with a GCN2 mutation.Journal of virology · 2012Article
- Efficient amplification of chimeric adenovirus 5/40S vectors carrying the short fiber protein of Ad40 in suspension cell cultures.PloS one · 2012Article
- Article
- Article
- Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review).Experimental and therapeutic medicine · 2010Article
- Efficient delivery of angiostatin K1-5 into tumors following insertion of an NGR peptide into adenovirus capsid.Gene therapy · 2009Article
- Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer.Journal of virology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
While adenovirus (Ad) gene delivery vectors are useful in many gene therapy applications, their broad tropism means that they cannot be directed to a specific target cell. There are also a number of cell types involved in human disease which are not transducible with standard Ad vectors, such as Epstein-Barr virus (EBV)-transformed B lymphocytes. Adenovirus binds to host cells via the viral fiber protein, and Ad vectors have previously been retargeted by modifying the fiber gene on the viral chromosome. This requires that the modified fiber be able to bind to the cell in which the vector is grown, which prevents truly specific vector targeting. We previously reported a gene delivery system based on a fiber gene-deleted Ad type 5 (Ad5) vector (Ad5.betagal.DeltaF) and packaging cells that express the viral fiber protein. Expression of different fibers in packaging cells will allow Ad retargeting without modifying the viral chromosome. Importantly, fiber proteins which can no longer bind to the producer cells can also be used. Using this approach, we generated for the first time pseudotyped Ad5.betagal.DeltaF particles containing either the wild-type Ad5 fiber protein or a chimeric fiber with the receptor-binding knob domain of the Ad3 fiber. Particles equipped with the chimeric fiber bound to the Ad3 receptor rather than the coxsackievirus-adenovirus receptor protein used by Ad5. EBV-transformed B lymphocytes were infected efficiently by the Ad3-pseudotyped particles but poorly by virus containing the Ad5 fiber protein. The strategy described here represents a broadly applicable method for targeting gene delivery to specific cell types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.